Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Up 6.19%
As of Friday, August 21, Allogene Therapeutics, Inc.’s ALLO share price has surged by 6.19%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Up 5.87%
As of Wednesday, August 19, Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.87%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Down 5.03%
As of Friday, July 31, Allogene Therapeutics, Inc.’s ALLO share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Up 8.29%
As of Thursday, July 30, Allogene Therapeutics, Inc.’s ALLO share price has surged by 8.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Down 7.14%
As of Tuesday, July 28, Allogene Therapeutics, Inc.’s ALLO share price has dipped by 7.14%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | ALLO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $725.5 | $286.3 | 41% |
|
| Shares Out (Mil) | 328.9 | 54.2 | 84% |
|
| Institutional Ownership | 93.4% | 92.8% | 63% |
|
| Float (Mil) | 267.3 | 39.7 | 78% |
|
| Beta | 0.47 | 0.94 | 27% |
|
| Avg Daily Volume (000s) | 4,989 | 534 | 92% |
|
| Price Change (52-week) |
99.5% | 58.7% | 91% |
|
| Growth | ALLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 9.6% | (10.1%) | 54% |
|
| EPS (5yr) | 19.9% | 16.0% | 68 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (24.6%) | (15.6%) | 26% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.141) | ($0.586) | ($0.702) | |
| Month Ago EPS | ($0.142) | ($0.608) | ($0.684) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.155) | ($0.642) | ($0.769) | |
| Year/Year Chg | 8.5% | (32.3%) | (41.7%) | |
| Financials | ALLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $37 | 5% |
|
| Net Income (TTM) (Mil) | ($166) | ($43) | 8% |
|
| EPS (TTM) | ($0.650) | ($1.400) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($102) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($14) | $2 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $70 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $431 | $160 | 33% |
|
| Valuation | ALLO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.66 | 2.77 | 43% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ALLO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (32.4%) | (47.3%) | 16% |
|
| ROE | (42.4%) | (55.0%) | 17% |
|
| Liabilities to Assets | 20.7% | 29.6% | 14% |
|
| F-Score | 3 | 2 | 18% |
|
Allogene Therapeutics, Inc. did not pass any screens on 8/20/2026.
